Psychiatric patient stratification using biosignatures based on cerebrospinal fluid protein expression clusters

Journal of Psychiatric Research

Volumn 47, Issue 11, 2013, Pages 1572-1580

  Maccarrone, Giuseppina ^a   Ditzen, Claudia ^a   Yassouridis, Alexander ^a   Rewerts, Christiane ^a   Uhr, Manfred ^a   Uhlen, Mathias ^b   Holsboer, Florian ^a   Turck, Christoph W ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b ALBANOVA UNIVERSITY CENTER   (Sweden)

Author keywords

Biosignatures; Cerebrospinal fluid; Multiplex analysis; Protein clusters; Protein levels; Psychiatric patient group stratification

Indexed keywords

ACTIN CAPPING PROTEIN; BETA1 INTEGRIN; BREVICAN; CELL ADHESION MOLECULE; CHROMOGRANIN A; CHROMOGRANIN B; CYSTATIN C; EXCITATORY AMINO ACID TRANSPORTER 2; FIBRONECTIN; GANGLIOSIDE GM2 ACTIVATOR PROTEIN; GLUTATHIONE PEROXIDASE 1; GLUTATHIONE PEROXIDASE 3; GUANINE NUCLEOTIDE BINDING PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; LIPOCORTIN 1; MICROTUBULE ASSOCIATED PROTEIN 2; OLIGODENDROCYTE MYELIN GLYCOPROTEIN; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; PLASMA MEMBRANE CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; PRESENILIN 1; PROENKEPHALIN; PROTEIN; PROTEIN TYROSINE PHOSPHATASE; SECRETOGRANIN II; SOLUBLE N ETHYLMALEIMIDE SENSITIVE FACTOR ATTACHMENT PROTEIN; SPECTRIN; SYNAPSIN; SYNAPTOJANIN; SYNAPTOPHYSIN; VALOSIN CONTAINING PROTEIN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; BIPOLAR DISORDER; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; IMAGE ANALYSIS; IMMUNOBLOTTING; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; NERVE CELL DIFFERENTIATION; NERVE CELL GROWTH; NEUROPROTECTION; NEUROTRANSMISSION; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PHENOTYPE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RELIABILITY; REPRODUCIBILITY; SCHIZOPHRENIA;

BIOSIGNATURES; CEREBROSPINAL FLUID; MULTIPLEX ANALYSIS; PROTEIN CLUSTERS; PROTEIN LEVELS; PSYCHIATRIC PATIENT GROUP STRATIFICATION;

ADULT; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES, NEURONAL; CLUSTER ANALYSIS; FEMALE; GLUTATHIONE PEROXIDASE; GPI-LINKED PROTEINS; HUMANS; MALE; MEMBRANE PROTEINS; MENTAL DISORDERS; MIDDLE AGED; NERVE TISSUE PROTEINS; PROTEIN ARRAY ANALYSIS; YOUNG ADULT;

EID: 84884412202     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.07.021     Document Type: Article

References (35)

1. aan het Rot M., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. Canadian Medical Association Journal 2009, 180:305-313.
2. Agaton C., Galli J., Hoiden Guthenberg I., Janzon L., Hansson M., Asplund A., et al. Affinity proteomics for systematic protein profiling of chromosome 21 gene products in human tissues. Molecular Cellular Proteomics 2003, 2:405-414.
3. Alaerts M., Del-Favero J. Searching genetic risk factors for schizophrenia and bipolar disorder: learn from the past and back to the future. Human Mutation 2009, 30:1139-1152.
4. American Psychiatric Association Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Press, Washington, DC. 4th ed.
5. Angst J., Sellaro R., Stassen H.H., Gamma A. Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions. Journal of Affective Disorders 2005, 84:149-157.
6. Bartolomucci A., Possenti R., Mahata S.K., Fischer-Colbrie R., Loh Y.P., Salton S.R. The extended granin family: structure, function, and biomedical implications. Endocrine Reviews 2011, 32:755-797.
7. Binder E.B., Nemeroff C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Molecular Psychiatry 2010, 15:574-588.
8. Blackwood D.H., Pickard B.J., Thomson P.A., Evans K.L., Porteous D.J., Muir W.J. Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1. Neurotoxicity Research 2007, 11:73-83.
9. Bremner J.D., Narayan M., Anderson E.R., Staib L.H., Miller H.L., Charney D.S. Hippocampal volume reduction in major depression. American Journal of Psychiatry 2000, 157:115-118.
10. Carpenter L.L., Heninger G.R., Malison R.T., Tyrka A.R., Price L.H. Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression. Journal of Affective Disorders 2004, 79:285-289.
11. Cichon S., Mühleisen T.W., Degenhardt F.A., Mattheisen M., Miró X., Strohmaier J., et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. American Journal of Human Genetics 2011, 88:372-381.
12. Cross-Disorder Group of the Psychiatric Genomics Consortium, Smoller J.W., Craddock N., Kendler K., Lee P.H., Neale B.M., et al. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013 Apr 20, 381(9875):1371-1379. 10.1016/S0140-6736(12)62129-1.
13. De Bellis M.D., Geracioti T.D., Altemus M., Kling M.A. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. Biological Psychiatry 1993, 33:636-641.
14. Ditzen C., Tang N., Jastorff A.M., Teplytska L., Yassouridis A., Maccarrone G., et al. Cerebrospinal fluid biomarkers for major depression confirm relevance of associated pathophysiology. Neuropsychopharmacology 2012, 37:1013-1025.
15. Falkai P., Mike O., Inez M.G., Paul H., Andras B.G., Sophia F., et al. Aroadmap to disentangle the molecular etiology of schizophrenia. European Psychiatry 2008, 23:224-232.
16. Ftouh S., Akbar M.T., Hirsch S.R., de Belleroche J.S. Down-regulation of Dickkopf 3, a regulator of the Wnt signalling pathway, in elderly schizophrenic subjects. Journal of Neurochemistry 2005, 94:520-530.
17. Gjerris A. Baseline studies on transmitter substances in cerebrospinal fluid in depression. Acta Psychiatrica Scandinavica 1988, 346(Suppl.):1-35.
18. Holsboer F. How can we realize the promise of personalized antidepressant medicines?. Nature Reviews Neuroscience 2008, 9:638-646.
19. Holsboer F., Ising M. Stress hormone regulation: biological role and translation into therapy. Annual Review of Psychology 2010, 61:81-109. C1-11.
20. Huang J.T., Leweke F.M., Oxley D., Wang L., Harris N., Koethe D., et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLOS Medicine 2006 Nov, 3(11):e428.
21. Krupnik V.E., Sharp J.D., Jiang C., Robison K., Chickering T.W., Amaravadi L., et al. Functional and structural diversity of the human Dickkopf gene family. Gene 1999, 238:301-313.
22. Maccarrone G., Birg I., Malisch E., Rosenhagen M.C., Ditzen C., Chakel J.A., et al. In-depth analysis of the human CSF proteome using protein prefractionation. Clinical Proteomics 2004, 1:333-364.
23. Mahuran D.J. Biochemical consequences of mutations causing the GM2 gangliosidoses. Biochimica et Biophysica Acta 1999, 1455:105-138.
24. McMahon F.J., Insel T.R. Pharmacogenomics and personalized medicine in neuropsychiatry. Neuron 2012, 74:773-776.
25. Meisenzahl E.M., Koutsouleris N., Bottlender R., Scheuerecker J., Jäger M., Teipel S.J., et al. Structural brain alterations at different stages of schizophrenia: avoxel-based morphometric study. Schizophrenia Research 2008, 104:44-60.
26. Moskvina V., Craddock N., Holmans P., Nikolov I., Pahwa J.S., Green E., et al. Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk. Molecular Psychiatry 2009, 14:252-260.
27. Nilsson P., Paavilainen L., Larsson K., Odling J., Sundberg M., Andersson A.C., et al. Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling. Proteomics 2005, 5:4327-4337.
28. Pawlak M., Schick E., Bopp M.A., Schneider M.J., Oroszlan P., Ehrat M. Zeptosens' protein microarrays: a novel high performance microarray platform for low abundance protein analysis. Proteomics 2002, 2:383-393.
29. Prasad K.M., Talkowski M.E., Chowdari K.V., McClain L., Yolken R.H., Nimgaonkar V.L. Candidate genes and their interactions with other genetic/environmental risk factors in the etiology of schizophrenia. Brain Research Bulletin 2010, 83:86-92.
30. Schwarz E., Bahn S. Cerebrospinal fluid: identification of diagnostic markers for schizophrenia. Expert Review of Molecular Diagnostics 2008 Mar, 8(2):209-216. 10.1586/14737159.8.2.209.
31. Voshol H., Ehrat M., Traenkle J., Bertrand E., van Oostrum J. Antibody-based proteomics: analysis of signaling networks using reverse protein arrays. FEBS Journal 2009, 276:6871-6879.
32. World Health Organization International statistical classification of diseases and related health problems 2010, 10th Revision.
33. Yassouridis A., Ludwig T., Steiger A., Leisch F. Anew way of identifying biomarkers in biomedical basic-research studies. PLOS ONE 2012, 7:e35741.
34. Yuan X., Russell T., Wood G., Desiderio D.M. Analysis of the human lumbar cerebrospinal fluid proteome. Electrophoresis 2002, 23:1185-1196.
35. Zougman A., Pilch B., Podtelejnikov A., Kiehntopf M., Schnabel C., Kumar C., et al. Integrated analysis of the cerebrospinal fluid peptidome and proteome. Journal of Proteome Research 2008, 7:386-399.